News Digest / Ticker: URGN

Ticker: URGN

09:07am, Monday, May 12, 2025

UroGen Pharma Reports Q1 2025: Revenue Grows Amid Rising Losses and Operational Challenges

UroGen Pharma Ltd. (NASDAQ: URGN) - Q1 2025 Financial Overview UroGen Pharma, a biotechnology company focused on treating urothelial and specialty cancers, released its Q1 2025 financials, showcasing a mixed performance. The company's current product, Jelmyto, is navigating a segment of oncology ...